Eloísa Riva
Impact in
-
- Multiple Myeloma Research and Treatments
-
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Hematology 20
- Multiple Myeloma Research and Treatments 18
-
- Protein Degradation and Inhibitors 5
- Amyloidosis: Diagnosis, Treatment, Outcomes 4
- Co-authors
- Pablo Cabral (10 shared papers)Marcelo Fernández (10 shared papers)F. Girotti (1 shared paper)T. Caraceni (1 shared paper)G. Calderini (1 shared paper)P. L. Morselli (1 shared paper)Juan Pablo Gambini (9 shared papers)S. Algeri (1 shared paper)
In The Last Decade
Eloísa Riva
34 papers receiving 154 citations
Peers
Comparison fields: 5 of 50
- Hematology 47
- Radiology, Nuclear Medicine and Imaging 38
- Cellular and Molecular Neuroscience 29
- Oncology 38
- Neurology 19
Countries citing papers authored by Eloísa Riva
This map shows the geographic impact of Eloísa Riva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eloísa Riva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eloísa Riva more than expected).
Fields of papers citing papers by Eloísa Riva
This network shows the impact of papers produced by Eloísa Riva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eloísa Riva. The network helps show where Eloísa Riva may publish in the future.
Co-authors
The 25 scholars most cited alongside Eloísa Riva, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1977 | 31 | |
| 2 | 2011 | 15 | |
| 3 | 2017 | 14 | |
| 4 | 2020 | 12 | |
| 5 | 2017 | 11 | |
| 6 | 2020 | 7 | |
| 7 | 2016 | 7 | |
| 8 | 2022 | 5 | |
| 9 | 2021 | 5 | |
| 10 | 2020 | 5 | |
| 11 | 2022 | 4 | |
| 12 | 2016 | 4 | |
| 13 | 2018 | 4 | |
| 14 | 2017 | 4 | |
| 15 | 2018 | 3 | |
| 16 | 2015 | 3 | |
| 17 | 2020 | 3 | |
| 18 | 2023 | 2 | |
| 19 | 2015 | 2 | |
| 20 | 2019 | 2 |
About Eloísa Riva
Eloísa Riva is a scholar working on Hematology, Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 39 papers that have together received 161 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (18 papers), Peptidase Inhibition and Analysis (9 papers), Radiopharmaceutical Chemistry and Applications (9 papers), Protein Degradation and Inhibitors (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Hematology (47 citations), Radiology, Nuclear Medicine and Imaging (38 citations), Cellular and Molecular Neuroscience (29 citations), Oncology (38 citations) and Neurology (19 citations). Eloísa Riva has collaborated with scholars based in Uruguay, Brazil and Argentina. Frequent co-authors include Pablo Cabral, Marcelo Fernández, F. Girotti, T. Caraceni, G. Calderini, P. L. Morselli, Juan Pablo Gambini, S. Algeri, A. Consolazione and Roger Chammas. Their work appears in journals such as Blood, Annals of Hematology, Amyloid, Anti-Cancer Agents in Medicinal Chemistry and Applied Radiation and Isotopes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.